Bellafill is the closest thing to a permanent filler on the US market, and Juvederm is not permanent at all. Bellafill's active component is polymethylmethacrylate microspheres, 30 to 50 microns across - tiny acrylic beads suspended in a solution of bovine collagen, lidocaine and buffered water. The body does not absorb them. They stay. Juvederm products are hyaluronic acid gels that the body breaks down, and that an enzyme can break down on demand.
That makes this a different kind of decision from most filler comparisons. With a Juvederm product, a result you dislike has two exits: wait, or dissolve it. With Bellafill, the microspheres have no exit. The FDA's own description of polymethylmethacrylate is "tiny, round, smooth particles that are not absorbed by the body," and the published literature on permanent fillers records no documented spontaneous or induced degradation. The only definitive removal is surgery.
Bellafill also requires a skin test first, and Juvederm does not. The microspheres are suspended in cow collagen, and its 2006 approval required pre-treatment skin testing for bovine collagen sensitivity before injection. Ask the clinic when they do the test, when they read it, and what happens if it is positive — that conversation is part of the treatment, not paperwork.
Neither of these is a brand you can talk about as one product. Bellafill is approved for two things: nasolabial folds, and certain acne scars on the cheek. Juvederm is a family — Ultra XC, Ultra Plus XC, Voluma XC, Vollure XC, Volbella XC, Volux XC and Skinvive — each with its own approval, its own area and its own duration figure.
Volbella XC is 15 mg/mL, Vollure XC 17.5 mg/mL, Voluma XC 20 mg/mL, Ultra XC and Ultra Plus XC 24 mg/mL, Volux XC 25 mg/mL.
The bovine collagen carrier is resorbed over roughly one to three months, while your own collagen forms around the beads. The beads are non-resorbable by design and stay where they are placed.
Separate MRI work has found hyaluronic acid signal detectable for years afterwards in a small selected group of patients — but a signal on a scan is not the same as a visible result.
Hyaluronidase has no target in an acrylic polymer. Steroid injections are used for inflammatory lumps, but they treat the reaction, not the material.
Expert guidance notes that the Vycross-family products need far more enzyme, describing hundreds of units to dissolve 1 cc, and a laboratory comparison found Juvederm among the most resistant products tested, needing 300 units for degradation within an hour.
The test exists because the carrier is cow-derived. Ask the clinic how far ahead of treatment they place it and when they read it.
The acne scar indication was added in December 2014; the original 2006 approval, as ArteFill, was for nasolabial folds only.
Facial wrinkles and folds: Ultra XC, Ultra Plus XC, Vollure XC. Lips: Ultra XC, Volbella XC — not Ultra Plus XC. Cheeks and chin: Voluma XC, which added a temple indication in 2023. Jawline definition: Volux XC. Under-eye hollows: Volbella XC. Skin smoothness of the cheeks and, since 2026, neck lines: Skinvive.
1,008 people were enrolled and 871 completed the full five years. They were questioned regularly for signs of granuloma, and anything suspicious was biopsied. Biopsy-confirmed granuloma occurred in 1.7%, and 0.9% still had an unresolved granuloma when the study ended. Satisfaction "remained high." There was no blinded wrinkle scale and no control group at five years. An employee of the manufacturer was a co-author.
Voluma XC in cheeks: 85.6% at month 6, 85.2% at month 12, 67.1% at month 24. Ultra XC in lips: 79.1% at month 3, 56.4% at month 12. Vollure XC in nasolabial folds: 93.2% at month 6, 59.4% at month 18. Volbella XC in lips: 61.8% at month 12. Volux XC on the jawline: 61.3% at month 12. Skinvive in cheeks: 55.6% at month 6.
A permanent filler does not hold a permanent face. The microspheres stay the same; the face around them does not. Fat pads, bone and skin all change over the following decades, and product placed to suit a face at 40 sits in a different landscape at 60. That is a structural argument for conservative volumes that has nothing to do with side effects.
Second, permanence changes what a complication means. A delayed inflammatory lump around a hyaluronic acid filler can, in the end, be dissolved. Around polymethylmethacrylate it cannot. The published record includes a woman with a draining cheek abscess of three years' standing in whom excision revealed polymethylmethacrylate microspheres and hyaluronic acid together with granulomatous inflammation; it resolved with surgery. That is a case report, not a rate, but it shows what the endpoint of a refractory problem looks like when the material cannot be broken down.
Third, the placement has to be right the first time. Bellafill's approval documents record a post-market report of one case of blindness following periorbital injection, in an off-label use — that area is not among its approved indications. Blindness from filler is rare and is reported with every material, but with an irreversible one there is no enzyme to reach for.
Bellafill's 2006 pivotal trial was randomised and double-masked, with 251 treated people — 128 on the product and 123 on a bovine collagen comparator. The primary endpoint was wrinkle improvement at six months, which the product met with statistical superiority over that comparator. Lumpiness was reported in 4.6%, and there was one severe adverse event, a granuloma.
The 2014 acne scar trial randomised people two to one against a saline control: 97 treated, 50 control. 64% of the Bellafill group reached at least a two-point improvement on a four-point acne scar scale across at least half their treated scars at six months, against 33% of controls. The last measurement was at twelve months. Treatment-related adverse events occurred in 9.8%, with no granulomas during the trial itself.
The number people quote — five years — comes from the surveillance study described in the lanes above, which measured granulomas and satisfaction rather than appearance. Marketing describing Bellafill as "the only FDA-approved filler that lasts 5 years" is a framing of that study, not of a five-year efficacy result.
No trial has compared Bellafill against any Juvederm product. Their figures come from separate trials with different scales, different comparators and different endpoints.
The only dated society figure is from 2023, the last year the American Society of Plastic Surgeons published filler fees: $901 for non-hyaluronic acid fillers, the group Bellafill sits in, against $715 for hyaluronic acid fillers. Those are per-procedure surgeon fees, not per-syringe prices, and they exclude facility costs. The more useful cost question here is not the sticker: a permanent product removes the repeat purchase, and it also removes the chance to stop.
Go to an emergency department or call 911 for any of these after any filler injection:
Sudden change or loss of vision in either eye
Sudden severe pain, or pain out of proportion to the procedure
Skin turning white or blanched, then dusky, grey or mottled
Weakness, drooping, slurred speech or any stroke-like symptom
These can mean filler has entered an artery, and the window is measured in hours. With Bellafill this matters more, not less. When a hyaluronic acid filler blocks a vessel, high-dose hyaluronidase is the emergency treatment; polymethylmethacrylate has no reversal agent at all. Do not wait to see whether it hurts — in a survey of experienced injectors describing their own intravascular injections, pain was mild or absent in 47% of events.
Swelling is still increasing after the first few days instead of settling
A lump appears, or a lump that was there is getting firmer rather than softer
Redness spreads outward from the site, or you develop a fever
An area becomes red, tender or swollen weeks, months or years later — with a permanent filler, late reactions remain possible indefinitely
The area looks uneven or the product seems to have shifted